Using Whole Transcriptome and Whole Exome Sequencing to Maximize Cancer Treatment
Growth of RNA sequencing allows physicians and researchers to analyze a patient’s full genetic profile.
Read MorePosted by Laurie Bonner | Jan 13, 2021 | Cancer, Molecular Diagnostics |
Growth of RNA sequencing allows physicians and researchers to analyze a patient’s full genetic profile.
Read MorePosted by Melanie Hamilton-Basich | Nov 17, 2020 | Flow Cytometry, Lung Cancer |
The test validation trial resulted in CyPath Lung specificity of 88% and sensitivity of 82%, similar to far more invasive procedures currently used to diagnose lung cancer.
Read MorePosted by Laurie Bonner | Nov 4, 2020 | Covid 19, Immunoassay Reagents & test Kits |
Engineered recombinant antibodies offer advantages over serum-based controls.
Read MorePosted by Melanie Hamilton-Basich | Oct 30, 2020 | Lung Cancer |
The group claim will also enable the test to be used as a CDx for any future approved EGFR TKI therapies targeting the same mutations.
Read MorePosted by Melanie Hamilton-Basich | Oct 27, 2020 | Breast, Lung Cancer, Unknown Origin & Other Cancer Types |
FDA approved FoundationOne Liquid CDx for three new companion diagnostic indications: Piqray in advanced or metastatic breast cancer; Rubraca in advanced ovarian cancer; and Alecensa in a certain type of metastatic non-small cell lung cancer.
Read More